Skip to main content
. Author manuscript; available in PMC: 2018 May 8.
Published in final edited form as: Clin Chem. 2012 Oct 24;59(1):119–126. doi: 10.1373/clinchem.2012.184572

Table 1. Proteomic technologies for the identification of tumor antigens that elicit autoantibodies.

Advantages Limitations
Recombinant protein arrays Content spans nearly the entire complement of proteins encoded in the genome Not suited for epitopes associated with posttranslational modifications
Natural protein arrays Well suited for epitopes associated with posttranslational modifications Require isolation from tumor sources and verification of antigen identity
Peptide arrays Scope covers the entire complement of peptides encoded in the genome Limited to linear epitopes
Mass spectrometry identification of antigen bound to Ig or soluble HLA molecules Allows detection of bound antigen Complexes may be cleared from the circulation and thus not detectable